Kumar K V S Hari, Vamsikrishna P, Verma A, Muthukrishnan J, Rayudu B Ramasubba, Modi K D
Department of Endocrinology, Medwin Hospitals, Nampally, Hyderabad-500001, AP, India.
West Indian Med J. 2009 Dec;58(6):566-70.
Assessment of thyroid blood flow gives valuable information about underlying functional status. Colour Flow Doppler Sonography (CFDS) is a powerful tool which displays tissue blood flow and vascularity. Colour Flow Doppler Sonography of the thyroid gland in different subsets of patients with Graves' disease was studied to define its role in initial diagnosis and management.
Eighty consecutive patients with Graves' disease (both treated and untreated) presented to hospital between August 2007 and February 2008. All patients were evaluated with CFDS of the thyroid for size, vascularity and peak systolic velocity (PSV) of the Inferior Thyroid Artery (ITA). Pertechnate scan and thyroidal autoantibody levels were done in selected cases. The patients were divided into Untreated Graves' disease (n = 31), Graves' disease on treatment but hyperthyroid (n = 26) and euthyroid Graves' disease on therapy (n = 23). Mann-Whitney U-test was used for statistical analysis and a p-value of less than 0.05 was considered significant.
Thyroid blood flow, as assessed by PSV of ITA, was significantly higher in untreated Graves' disease than in Graves disease on treatment but hyperthyroid and euthyroid Graves respectively (61.5 +/- 19.5 versus 42.9 +/- 24.7 versus 32.2 +/- 12.9 cm/s, p < 0.05). Parenchymal vascularity of the thyroid gland was higher in hyperthyroid patients than in euthyroid patients irrespective of therapy. In both groups on therapy, the dose of carbimazole correlated with the vascularity of the gland (r = 0.492 versus 0.564, p < 0.05). Colour Flow Doppler Sonography parameters correlated significantly with pertechnate scan results giving comparable sensitivity and specificity.
Assessment of thyroid blood flow by CFDS is an effective marker in the initial diagnosis of Graves' disease. Vascularity of the gland can predict long term disease course while on medical therapy.
评估甲状腺血流可为潜在的功能状态提供有价值的信息。彩色多普勒超声(CFDS)是一种显示组织血流和血管分布的强大工具。本研究对不同亚组格雷夫斯病患者的甲状腺进行彩色多普勒超声检查,以明确其在初始诊断和治疗中的作用。
2007年8月至2008年2月期间,连续80例格雷夫斯病患者(包括已治疗和未治疗的)入院。所有患者均接受甲状腺CFDS检查,以评估甲状腺大小、血管分布及甲状腺下动脉(ITA)的收缩期峰值流速(PSV)。部分病例进行了过锝酸盐扫描和甲状腺自身抗体水平检测。患者分为未治疗的格雷夫斯病组(n = 31)、治疗中仍为甲亢的格雷夫斯病组(n = 26)和治疗后甲状腺功能正常的格雷夫斯病组(n = 23)。采用曼-惠特尼U检验进行统计分析,p值小于0.05被认为具有统计学意义。
通过ITA的PSV评估,未治疗的格雷夫斯病患者的甲状腺血流显著高于治疗中仍为甲亢的格雷夫斯病患者和治疗后甲状腺功能正常的格雷夫斯病患者(分别为61.5±19.5 cm/s、42.9±24.7 cm/s和32.2±12.9 cm/s,p < 0.05)。无论是否接受治疗,甲亢患者甲状腺实质血管分布均高于甲状腺功能正常的患者。在两组接受治疗的患者中,甲巯咪唑剂量与腺体血管分布相关(r = 0.492和0.564,p < 0.05)。彩色多普勒超声参数与过锝酸盐扫描结果显著相关,敏感性和特异性相当。
CFDS评估甲状腺血流是格雷夫斯病初始诊断的有效指标。在药物治疗期间,腺体血管分布可预测疾病的长期病程。